Drug profile · INN
etrasimod
VELSIPITY
etrasimod (VELSIPITY) is a sphingosine 1-phosphate receptor edg-6 modulator. Associated with Pfizer Australia Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04AE05
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — etrasimod
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
etrasimod (VELSIPITY) is a sphingosine 1-phosphate receptor edg-6 modulator. Associated with Pfizer Australia Pty Ltd.
Key facts
INN etrasimod
Brand VELSIPITY
Mechanism Sphingosine 1-phosphate receptor Edg-6 modulator
Target Sphingosine 1-phosphate receptor 1
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AE05
Originator Pfizer Australia Pty Ltd
Mechanism of action
Sphingosine 1-phosphate receptor Edg-6 modulator
Primary target: Sphingosine 1-phosphate receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is etrasimod?
etrasimod (VELSIPITY) is a sphingosine 1-phosphate receptor edg-6 modulator. Associated with Pfizer Australia Pty Ltd.
What is the brand name for etrasimod?
VELSIPITY is a marketed brand name for etrasimod. Check FDA Drugs@FDA for the current US label holder and prescribing information.